NASDAQ:TOCA - Tocagen Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$29.16
▲ +0.33 (1.14%)
Get New Tocagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TOCA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TOCA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Tocagen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $29.16.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Tocagen. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2020Chardan CapitalReiterated RatingHold$1.00N/A
i
Rating by Geulah Livshits at Chardan Capital
11/25/2019Chardan CapitalReiterated RatingHoldHigh
i
Rating by Y. Livshits at Chardan Capital
11/14/2019HC WainwrightReiterated RatingHoldMedium
i
Rating by S. Ramakanth at HC Wainwright
11/13/2019Chardan CapitalReiterated RatingHold$1.00High
i
Rating by Y. Livshits at Chardan Capital
10/17/2019Cantor FitzgeraldReiterated RatingNeutralHigh
i
Rating by V. Kumar at Cantor Fitzgerald
10/3/2019Chardan CapitalDowngradeHold$1.00High
i
Rating by Y. Livshits at Chardan Capital
9/13/2019CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $1.00High
i
9/13/2019Chardan CapitalDowngradeBuy ➝ Neutral$1.00High
i
Rating by Geulah Livshits at Chardan Capital
9/12/2019B. RileyDowngradeBuy ➝ NeutralHigh
i
Rating by G. Zavoico at B. Riley
9/12/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
i
9/12/2019HC WainwrightDowngradeBuy ➝ Neutral$3.32N/A
i
Rating by S. Ramakanth at HC Wainwright
9/12/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralN/A
i
Rating by E. Piros at Cantor Fitzgerald
9/12/2019Robert W. BairdDowngradeOutperform ➝ NeutralN/A
i
8/9/2019HC WainwrightReiterated RatingBuyHigh
i
5/30/2019CitigroupInitiated CoverageBuyHigh
i
5/22/2019SVB LeerinkSet Price TargetHold$5.00High
i
Rating by Daina Graybosch at SVB Leerink LLC
5/22/2019Chardan CapitalReiterated RatingBuy$10.00High
i
Rating by Geulah Livshits at Chardan Capital
5/14/2019Chardan CapitalSet Price TargetBuy$25.00Low
i
Rating by Geulah Livshits at Chardan Capital
5/9/2019HC WainwrightReiterated RatingBuy$14.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/25/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$28.00High
i
Rating by E. Piros at Cantor Fitzgerald
4/23/2019Chardan CapitalReiterated RatingBuyHigh
i
Rating by Y. Livshits at Chardan Capital
4/15/2019SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$11.00Medium
i
Rating by M. Schmidt at SVB Leerink LLC
1/18/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$20.00Medium
i
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$22.00 ➝ $22.00Medium
i
Rating by G. Zavoico at B. Riley
11/12/2018HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/20/2018B. RileyBoost Price TargetBuy ➝ Buy$15.00 ➝ $22.00Low
i
Rating by M. Kumar at B. Riley
9/4/2018CitigroupInitiated CoverageBuy$27.00High
i
8/30/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$30.00High
i
Rating by G. Amusa at Chardan Capital
6/27/2018LADENBURG THALM/SH SHInitiated CoverageBuy$20.00Medium
i
6/11/2018HC WainwrightInitiated CoverageBuy$14.50Low
i
Rating by S. Ramakanth at HC Wainwright
5/16/2018B. RileyInitiated CoverageBuy$15.00High
i
Rating by M. Kumar at B. Riley
7/25/2017Stifel NicolausReiterated RatingBuy$24.00Low
i
5/15/2017Stifel NicolausInitiated CoverageBuy$24.00Medium
i
5/15/2017SVB LeerinkInitiated CoverageMkt Perform$19.00Medium
i
Rating by M. Schmidt at SVB Leerink LLC
5/9/2017Evercore ISIReiterated RatingOutperform$28.00Low
i
5/8/2017SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$19.00High
i
Rating by M. Schmidt at SVB Leerink LLC
5/8/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$24.00Medium
i
(Data available from 2/25/2016 forward)
Tocagen logo
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $29.16
$27.51
$31.63

50 Day Range

MA: $32.24
$1.26
$41.03

52 Week Range

Now: $29.16
$0.42
$6.77

Volume

104,946 shs

Average Volume

1,472,422 shs

Market Capitalization

$697.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Tocagen?

The following Wall Street sell-side analysts have issued reports on Tocagen in the last year: Zacks Investment Research.
View the latest analyst ratings for TOCA.

What is the current price target for Tocagen?

0 Wall Street analysts have set twelve-month price targets for Tocagen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Tocagen in the next year.
View the latest price targets for TOCA.

What is the current consensus analyst rating for Tocagen?

Tocagen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TOCA.

What other companies compete with Tocagen?

How do I contact Tocagen's investor relations team?

Tocagen's physical mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company's listed phone number is 858-412-8400 and its investor relations email address is [email protected] The official website for Tocagen is www.tocagen.com.